Radiopharm Theranostics Reports Encouraging Initial Phase 1 Data for 177Lu-RAD202 in HER2+ Solid Tumors
RADX sits 25% above its 52-week low of $3.62 on light trading volume (0.2× avg).
Summary
Radiopharm Theranostics announced positive initial findings from its Phase 1 HEAT trial for 177Lu-RAD202, demonstrating encouraging tumor uptake and a favorable safety profile in HER2+ solid tumors, supporting continued dose escalation.
Key Events · Product Development and Regulatory · RADX
-
Positive Phase 1 Initial Findings
177Lu-RAD202 demonstrated encouraging tumor uptake and a favorable safety profile in the lowest dose cohort of the HEAT trial for HER2+ solid tumors.
-
Favorable Safety Profile
No dose-limiting toxicities or treatment discontinuations due to adverse events were observed, with organ-level radiation doses within clinically acceptable ranges.
-
Dose Escalation Approved
The Data Safety and Monitoring Committee (DSMC) approved advancing 177Lu-RAD202 to the next highest dose at 130 mCi, following these positive initial results. This advancement was previously announced on April 8, 2026.
-
AACR Presentation
These first-in-human safety, biodistribution, dosimetry, and tumor uptake findings were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Analysis · RADX · Life Sciences
This 6-K filing provides crucial early clinical data for Radiopharm Theranostics' 177Lu-RAD202, a HER2-targeted radiopharmaceutical therapy. The positive safety profile and encouraging tumor uptake observed in the lowest dose cohort are significant milestones for a clinical-stage company. The Data Safety and Monitoring Committee's approval to advance to a higher dose level, which was previously announced on April 8, 2026, is now supported by these initial findings. These results, presented at AACR, de-risk the program and provide a foundation for future development, potentially attracting further investor interest.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RADX was trading at $4.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.1M. The 52-week trading range was $3.62 to $16.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.